Theriva Biologics (TOVX) News Today $1.28 +0.02 (+1.59%) (As of 11/21/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Theriva Biologics (NYSEAMERICAN:TOVX) Price Target Lowered to $6.00 at Maxim GroupNovember 15, 2024 | americanbankingnews.comTheriva Biologics Highlights Key Achievements in Q3 2024November 14, 2024 | tipranks.comTheriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial ResultsNovember 13, 2024 | markets.businessinsider.comTheriva Biologics, Inc.: Theriva Biologics Reports Third Quarter 2024 Operational Highlights and Financial ResultsNovember 12, 2024 | finanznachrichten.de3 Penny Stocks to Watch Now, 11/5/24November 5, 2024 | msn.comTheriva Biologics Expands Stock Plans and Share AuthorityNovember 2, 2024 | markets.businessinsider.comWhat's Going On With Theriva Biologics Stock Friday?November 2, 2024 | msn.comTheriva Biologics picked as finalist in competition for Merck KGaA’s EMEA grantNovember 1, 2024 | markets.businessinsider.comTheriva Biologics, Inc.: Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech GrantOctober 31, 2024 | finanznachrichten.deTheriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech GrantOctober 31, 2024 | markets.businessinsider.comTheriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of RetinoblastomaOctober 16, 2024 | globenewswire.comTheriva Biologics (AMEX:TOVX) Stock, Insider Trading ActivityOctober 4, 2024 | benzinga.comNano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant PatientsOctober 4, 2024 | finance.yahoo.comTheriva Biologics (AMEX:TOVX) Stock, Short Interest ReportSeptember 27, 2024 | benzinga.comTheriva Biologics dips 11%, prices 2.5M equity offeringSeptember 27, 2024 | msn.comTheriva Biologics Announces Pricing of $2.5 Million Public OfferingSeptember 26, 2024 | globenewswire.comTheriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic CancerSeptember 23, 2024 | globenewswire.comTheriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer ProgramSeptember 16, 2024 | markets.businessinsider.comTheriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer ProgramSeptember 16, 2024 | globenewswire.comTheriva Biologics (TOVX) Is Making Noise With a Promising PipelineSeptember 4, 2024 | msn.comTheriva Biologics (AMEX:TOVX) Stock Quotes, Forecast and News SummaryAugust 31, 2024 | benzinga.comWhat's Going On With Theriva Biologics Stock?August 30, 2024 | msn.comTheriva Biologics, Inc. (NYSEAMERICAN:TOVX) Sees Significant Decline in Short InterestTheriva Biologics, Inc. (NYSEAMERICAN:TOVX - Get Free Report) was the target of a significant drop in short interest during the month of August. As of August 15th, there was short interest totalling 4,000 shares, a drop of 91.4% from the July 31st total of 46,300 shares. Based on an average daily volume of 47,800 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company's stock are sold short.August 27, 2024 | marketbeat.comTheriva Biologics, Inc. (SFY.F)August 26, 2024 | nz.finance.yahoo.comWhat's Going On With Theriva Biologics (TOVX) Stock?August 20, 2024 | benzinga.comTheriva Biologics Announces 25-for-1 Reverse Stock SplitAugust 18, 2024 | marketwatch.comTheriva Biologics, Inc.: Theriva Biologics Announces Reverse Stock SplitAugust 16, 2024 | finanznachrichten.deTheriva Biologics Announces Reverse Stock SplitAugust 16, 2024 | globenewswire.comTheriva Biologics, Inc.: Theriva Biologics Reports Second Quarter 2024 Operational Highlights and Financial ResultsAugust 14, 2024 | finanznachrichten.deTOVX Stock Earnings: Theriva Biologics Beats EPS for Q2 2024August 13, 2024 | investorplace.comTheriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of RetinoblastomaJuly 31, 2024 | globenewswire.comTheriva gets FDA fast track status for VCN-01 for pancreatic cancerMay 23, 2024 | msn.comTheriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic CancerMay 23, 2024 | globenewswire.comTheriva Biologics, Inc. (TOVX)May 17, 2024 | finance.yahoo.comTheriva™ Biologics to Participate in the A.G.P. Virtual Healthcare ConferenceMay 14, 2024 | globenewswire.comTOVX Stock Earnings: Theriva Biologics Beats EPS for Q1 2024May 7, 2024 | investorplace.comTheriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial ResultsMay 7, 2024 | globenewswire.comTheriva reports progress in retinoblastoma treatment trialApril 25, 2024 | investing.comTheriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 25, 2024 | globenewswire.comTheriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory RetinoblastomaApril 23, 2024 | globenewswire.comTheriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual MeetingApril 22, 2024 | globenewswire.comTheriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat CancersApril 17, 2024 | benzinga.comTheriva Biologics, Inc.: Theriva Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual MeetingApril 8, 2024 | finanznachrichten.deTheriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual MeetingApril 8, 2024 | globenewswire.comTheriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | seekingalpha.comQ4 2023 Theriva Biologics Inc Earnings CallMarch 26, 2024 | finance.yahoo.comTheriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial ResultsMarch 25, 2024 | globenewswire.comPreview: Theriva Biologics's EarningsMarch 22, 2024 | benzinga.comTheriva Biologics, Inc.: Theriva Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial ResultsMarch 19, 2024 | finanznachrichten.deTheriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial ResultsMarch 19, 2024 | globenewswire.com Get Theriva Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for TOVX and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now TOVX Media Mentions By Week TOVX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TOVX News Sentiment▼-0.870.48▲Average Medical News Sentiment TOVX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TOVX Articles This Week▼11▲TOVX Articles Average Week Get Theriva Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for TOVX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRPOF News SLGL News NLSP News INTI News NRSN News SNSE News TLPH News EGRX News ATBPF News APLM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:TOVX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theriva Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theriva Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
